Rocket Pharmaceuticals, Inc.
RCKT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001281895
In the last 90 days, Rocket Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 7 sales; 180 institutions reported holding it in 13F filings for Q2 2026, worth $340.9M in total; Maverick Capital is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Rocket Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 194
- +20 vs. Q3 2023
- Shares held
- 89.0M
- −239.9K (−0.3%) vs. Q3 2023
- Total value
- $2.67B
- +$839.2M (+45.9%) vs. Q3 2023
- New holders
- 37
- 67 more added
- Sold out
- 17
- 66 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RCKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 180 | $340.9M |
| Q1 2026 | 199 | $347.9M |
| Q4 2025 | 186 | $320.0M |
| Q3 2025 | 173 | $314.8M |
| Q2 2025 | 196 | $233.0M |
| Q1 2025 | 236 | $722.5M |
| Q4 2024 | 225 | $1.38B |
| Q3 2024 | 192 | $1.71B |
| Q2 2024 | 178 | $1.96B |
| Q1 2024 | 185 | $2.48B |
| Q4 2023 | 194 | $2.67B |
| Q3 2023 | 175 | $1.83B |
| Q2 2023 | 164 | $1.52B |
| Q1 2023 | 163 | $1.34B |
| Q4 2022 | 168 | $1.49B |
| Q3 2022 | 164 | $1.10B |
| Q2 2022 | 147 | $891.6M |
| Q1 2022 | 149 | $1.02B |
| Q4 2021 | 148 | $1.38B |
| Q3 2021 | 147 | $1.85B |
| Q2 2021 | 150 | $2.74B |
| Q1 2021 | 173 | $2.75B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Rocket Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nebula Research & Development LLC | 0 | $0 | 0.00% | −21,435−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −11,269−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −10,400−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −5,197−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −5,145−100.0% | Sold out |
| Annandale Capital, LLC | 0 | $0 | 0.00% | −3,220−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Mendota Financial Group, LLC | 0 | $0 | 0.00% | −45−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| International Biotechnology Trust PLC | – | – | – | – | Not filed |